Seeking Alpha

Shire takes major hit on sale of Dermagraft therapy

  • Shire (SHPG) is taking a $650M loss on its Dermagraft treatment for the treatment of diabetic foot ulcers after selling the therapy to U.S.-based Organogenesis.
  • Shire isn't receiving any money up front, although it could get as much as $300M in revenue milestone payments.
  • Shire acquired Dermagraft when it bought Advanced BioHealing for $750M in June 2011, but soon after the deal, the FDA rejected the drug for treating leg ulcers.
  • SocGen analysts are happy that Shire is getting rid of a "non-core, loss-making product."
  • Shares are +0.6% in London. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: